Evidence map›Paper›PMID 42518342›Full record

ReviewFrontiers in pharmacology2026

Xinyue Yu, Liang He, Guoyu Li, Yuyan Guo, Haixue Kuang, Shaowa Lv

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Xinyue YuKey Laboratory of the Ministry of Education, Department of Pharmacology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Liang HeKey Laboratory of the Ministry of Education, Department of Pharmacology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Guoyu LiSchool of Pharmacy, Harbin University of Commerce, Harbin, China.
Yuyan GuoKey Laboratory of the Ministry of Education, Department of Pharmacology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Haixue KuangKey Laboratory of the Ministry of Education, Department of Pharmacology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.
Shaowa LvKey Laboratory of the Ministry of Education, Department of Pharmacology, Heilongjiang University of Chinese Medicine, Harbin, Heilongjiang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Rheumatoid arthritis (RA) is a systemic autoimmune disorder in which persistent synovitis drives progressive joint damage, often leading to functional limitation and a reduced quality of life. Purpose: This review aims to systematically integrate current knowledge on the ethnopharmacology, phytochemistry, pharmacokinetics, anti-RA pharmacological mechanisms, and applications of emerging technologies related to Methods: To compile evidence on Results: To date, more than 100 compounds have been isolated and identified from Conclusion: This review provides a comprehensive and integrated overview of

Indexed as

Caulophyllum robustum maximethnopharmacologypharmacokineticspharmacologyphytochemistryrheumatoid arthritis

Identifiers

PMID42518342
PMCPMC13382222

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.